# Faeth Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2023

- Company: [Faeth Therapeutics, Inc.](/companies/fth.md) (CIK 1829802)
- Form: 10-Q
- Filed: 2023-08-03
- Accepted by EDGAR: Aug 3, 2023, 16:32 ET
- Period: 2023-06-30
- Accession: 0000950170-23-038085
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1829802/000095017023038085/snse-20230630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1829802/000095017023038085/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 3 months, 2023-04-01 to 2023-06-30 | −$10.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2023-01-01 to 2023-06-30 | −$21.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2023-04-01 to 2023-06-30 | $38.0k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2023-01-01 to 2023-06-30 | $80.0k | us-gaap:InterestExpense |
| Income tax | 6 months, 2023-01-01 to 2023-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-04-01 to 2023-06-30 | −$9.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2023-01-01 to 2023-06-30 | −$19.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-04-01 to 2023-06-30 | −$0.31 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2023-01-01 to 2023-06-30 | −$0.64 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-04-01 to 2023-06-30 | −$0.31 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2023-01-01 to 2023-06-30 | −$0.64 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-04-01 to 2023-06-30 | 30,507,018 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2023-01-01 to 2023-06-30 | 30,685,561 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2023-01-01 to 2023-06-30 | −$21.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2023-01-01 to 2023-06-30 | $180.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months, 2023-01-01 to 2023-06-30 | $7.8m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2023-06-30 | $10.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-06-30 | $81.1m | us-gaap:AssetsCurrent |
| Total assets | at 2023-06-30 | $89.6m | us-gaap:Assets |
| Current liabilities | at 2023-06-30 | $5.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-06-30 | $10.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-06-30 | $79.2m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1829802/000095017023038085/snse-20230630.htm

Filed Aug 3, 2023.
Source: SEC EDGAR, the filing index for accession 0000950170-23-038085. Last ingested by Listed: Nov 3, 2026, 23:17 ET. No prices; not investment advice.